Toinv - thanks, appreciate the feedback.  It’s hard to know precisely what is really behind some of their comments, and the one about data being very enlightening for shareholders could just as easily end up being a nothingburger with DM just speaking in general terms.  But, when faced with disappointing news we try to find hope wherever we can.

I don’t think there is any doubt that much will be learned from the full data analysis but it might yet take another trial to confirm APLs potential in the CVD arena.  If we can get some positive data on the CKD and Cognition substudies then the next trial (?) might just end up being the blockbuster we were all hoping for with BETonMACE.  For now though we just wait on the AHA next month.

TickTock2